Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Lianjun Shen

Showing results (21-30 of 23) with videos related to

Pageof 3
Sort By:
You have reached the last page of results.This site can display upto 23 results.
Blood Cancer Journal|June 24, 2022
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemiaCheng Zhang, Jiaping He, Li Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2020
Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS ManagementShiqi Li, Xinxin Wang, Zhongtao Yuan, et al.
Leukemia|September 12, 2023
CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignanciesShiqi Li, Xinxin Wang, Lin Liu, et al.
Pageof 3

Showing results (21-30 of 23) with videos related to

Sort By:
Pageof 3
You have reached the last page of results.This site can display upto 23 results.
Blood Cancer Journal|June 24, 2022
Novel CD19 chimeric antigen receptor T cells manufactured next-day for acute lymphoblastic leukemiaCheng Zhang, Jiaping He, Li Liu, et al.
Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|November 25, 2020
Eradication of T-ALL Cells by CD7-targeted Universal CAR-T Cells and Initial Test of Ruxolitinib-based CRS ManagementShiqi Li, Xinxin Wang, Zhongtao Yuan, et al.
Leukemia|September 12, 2023
CD7 targeted "off-the-shelf" CAR-T demonstrates robust in vivo expansion and high efficacy in the treatment of patients with relapsed and refractory T cell malignanciesShiqi Li, Xinxin Wang, Lin Liu, et al.
Pageof 3